Press
Releases

KINETA_web_hp_redpoint

Press Releases

KINETA_web_hp_redpoint

Kineta Press Releases

Kineta to Participate in “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond” Virtual Symposium Seattle, WA — (June

Kineta Presents New Preclinical Data on its Lead VISTA Antagonist Antibody at the AACR Annual Meeting 2021 Seattle, WA —

Kineta Presents Clinical Study Results of LHF-535 at the International Conference on Antiviral Research (ICAR) Safety, tolerability and pharmacokinetic profile

Kineta Presenting at Multiple Investor Conferences in March 2021 Seattle, WA — (March 3, 2021) Kineta, Inc., a clinical stage

Kineta Announces First Participant Dosed in Phase 1 Clinical Trial of KCP506, A Novel Non-Opioid for the  Treatment of Chronic

Kineta Presents New Preclinical Data at ESMO Virtual Congress 2020 on its VISTA Antagonist Antibodies Seattle, WA — (December 9,

Kineta Presents New Preclinical Data at the 2020 SITC Annual Meeting on its VISTA Antagonist Antibodies Preclinical data demonstrates that

Kineta Presents New Preclinical Data on VISTA Antagonist Antibodies at AACR Conference on Tumor Immunology and Immunotherapy Seattle, WA —

Collaboration to advance a first-in-class α9/α10 nAchR antagonist for the treatment of chronic pain into Phase 1 clinical trials Seattle,

Disclaimer: The Press Releases on this page are provided for historical purposes only. The information contained in each [press release/news article/event] is accurate only as of the date each was originally issued. Kineta disavows any obligation to update the information after the date of their issuance.